Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFD-06 (Impoyz) in Pediatric Plaque Psoriasis
NCT03179605Phase 2Terminated
- Sponsor
- Primus Pharmaceuticals
- Start
- May 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clobetasol in plaque psoriasis, sponsored by Primus Pharmaceuticals. Primary endpoint: Percentage of Subjects With HPA Axis Suppression at Day 15. Started May 2017; status: terminated.
02
Drugs
clobetasol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03179605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03179605.